A prominent example is cetuximab (IgG1), which binds to the epidermal growth factor receptor (EGFR), thereby interrupting intracellular signaling pathways and inhibiting tumor cell proliferation [3,4,5]. This evidence concerns the gene EGFR and neoplasm.